# US 2016/0235844 A1 · Methods of treating neuroendocrine tumors using frizzled-binding agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235844 A1
- Document ID: US20160235844A1
- Status: Published application
- Kind: A1
- Application number: 14/993,775
- Filed: 2016-01-12
- Published: 2016-08-18
- Earliest claimed: 2012-10-23
- Assignees: OncoMed Pharmaceuticals, Inc.
- Applicants: OncoMed Pharmaceuticals, Inc.
- Inventors: Robert Joseph Stagg; Jakob Dupont
- Web page: https://patentgrep.com/patent/US20160235844A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/3053: {Skin, nerves, brain}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/02: containing a signal sequence
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a Wnt antagonist. In one embodiment, the Wnt antagonist is an anti-FZD antibody. In another embodiment, the Wnt antagonist is a soluble FZD receptor polypeptide. In a further embodiment, the Wnt antagonist is an anti-Wnt antibody.

## Claims

### Claim at position 1

1-6. (canceled)

### Claim 7

A method of treating neuroendocrine cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Wnt antagonist.

### Claim 8 (depends on 7)

The method of claim 7, wherein the subject is a human subject.

### Claim at position 4

9-10. (canceled)

### Claim 11 (depends on 7)

The method of claim 7, wherein the neuroendocrine tumor is selected from the group consisting of gastroenteropancreatic neuroendocrine tumor, carcinoid tumor, pheochromocytoma, paraganglioma, medullary thyroid cancer, pulmonary neuroendocrine tumor and thymic neuroendocrine tumor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the neuroendocrine tumor is a carcinoid tumor or a pancreatic neuroendocrine tumor.

### Claim 13 (depends on 7)

The method claim 7, wherein the Wnt antagonist is an antibody that binds to at least one human frizzled receptor (FZD).

### Claim at position 8

14-16. (canceled)

### Claim 17 (depends on 13)

The method of claim 13, wherein the antibody specifically binds to at least one human FZD selected from the group consisting of FZD1, FZD2, FZD5, FZD7, and FZD8.

### Claim at position 10

18-21. (canceled)

### Claim 22 (depends on 17)

The method of claim 17, wherein the antibody specifically binds to FZD1, FZD2, FZD5, FZD7, and FZD8.

### Claim 23

(canceled)

### Claim 24 (depends on 13)

The method of claim 13, wherein the antibody blocks Wnt binding to FZD or blocks the activation of FZD.

### Claim 25

(canceled)

### Claim 26 (depends on 13)

The method of claim 13, wherein the antibody comprises:
(a) a heavy chain CDR1 comprising GFTFSHYTLS (SEQ ID NO:31), a heavy chain CDR2 comprising VISGDGSYTYYADSVKG (SEQ ID NO:32), and a heavy chain CDR3 comprising NFIKYVFAN (SEQ ID NO:33); and/or
(b)
(i) a light chain CDR1 comprising SGDNIGSFYVH (SEQ ID NO:34), a light chain CDR2 comprising DKSNRPSG (SEQ ID NO:35), and a light chain CDR3 comprising QSYANTLSL (SEQ ID NO:36); or
(ii) a light chain CDR1 comprising SGDKLGKKYAS (SEQ ID NO:41), a light chain CDR2 comprising EKDNRPSG (SEQ ID NO:42), and a light chain CDR3 comprising SSFAGNSLE (SEQ ID NO:43).

### Claim 27 (depends on 26)

The method of claim 26, wherein the antibody comprises:
(a) a VH comprising the amino acid sequence of SEQ ID NO:37; and/or
(b) a VL comprising the amino acid sequence of SEQ ID NO:38 or 44.

### Claim 28 (depends on 26)

The method of claim 26, wherein the antibody comprises:
(a) a heavy chain comprising the amino acid sequence of SEQ ID NO:39; and/or
(b) a light chain comprising the amino acid sequence of SEQ ID NO:40 or 45.

### Claim 29 (depends on 13)

The method of claim 13, wherein the antibody is a monoclonal antibody.

### Claim 30 (depends on 29)

The method of claim 29, wherein the antibody is a recombinant antibody, a chimeric antibody, a humanized antibody, a human antibody, or an antibody fragment.

### Claim 31 (depends on 29)

The method of claim 29, wherein the antibody is a monospecific antibody or a bispecific antibody.

### Claim 32

(canceled)

### Claim 33 (depends on 13)

The method of claim 13, wherein the antibody is an IgG1 or IgG2 antibody.

### Claim 34 (depends on 7)

The method of claim 7, wherein the Wnt antagonist is a soluble FZD receptor that is capable of binding to Wnt.

### Claim at position 24

35-36. (canceled)

### Claim 37 (depends on 34)

The method of claim 34, wherein the soluble receptor comprises a fragment of the extracellular domain of the human FZD receptor, said fragment comprising the Fri domain of the human FZD receptor.

### Claim 38

(canceled)

### Claim 39 (depends on 37)

The method of claim 37, wherein the human FZD receptor is FZD8.

### Claim 40 (depends on 39)

The method of claim 39, wherein the FZD8 Fri domain comprises the amino acid sequence of SEQ ID NO: 28.

### Claim 41 (depends on 40)

The method of claim 40, wherein the soluble receptor further comprises a human Fc domain.

### Claim 42 (depends on 41)

The method of claim 41, wherein the human Fc domain comprises the amino acid sequence of SEQ ID NO: 95.

### Claim 43 (depends on 7)

The method of claim 7, which further comprises administering a second therapeutic agent to the subject.

### Claim 44 (depends on 43)

The method of claim 43, wherein the second therapeutic agent is a chemotherapeutic agent.

### Claim at position 33

45-48. (canceled)

### Claim 49 (depends on 7)

The method of claim 7, wherein the Wnt antagonist is OMP-18R5.

### Claim at position 35

50-52. (canceled)

### Claim 53 (depends on 7)

The method of claim 7, wherein the Wnt antagonist is OMP-54F28.

### Claim 54 (depends on 7)

The method of claim 7, wherein the neuroendocrine tumor is not small cell lung tumor (SCLC).

### Claim at position 38

55-56. (canceled)
